Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022

Rhea-AI Summary

Clearside Biomedical (NASDAQ: CLSD) will report its Q1 2022 financial results on May 11, 2022, post-market close. Following the announcement, management will host a webcast at 4:30 p.m. ET for discussion and corporate updates. Clearside Biomedical focuses on delivering therapies to the back of the eye via its proprietary SCS Microinjector, aiming to enhance vision in patients with sight-threatening conditions. The company’s product, XIPERE, is already available in the U.S.

Positive

• Clearside's SCS Microinjector allows for targeted delivery of therapies to the eye.
• The company has a commercial product, XIPERE, available in the U.S.

Negative

• None.

ALPHARETTA, Ga., April 29, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that its first quarter 2022 financial results will be reported on Wednesday, May 11, 2022 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domestic) or (213) 358-0959 (international) and entering conference code: 3749780. An archive of the webcast will be available for three months.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE^® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

FAQ

When will Clearside Biomedical report its Q1 2022 financial results?

Clearside Biomedical will report its Q1 2022 financial results on May 11, 2022, after the market closes.

What time is the Clearside Biomedical conference call for Q1 2022 results?

The conference call will take place at 4:30 p.m. Eastern Time on May 11, 2022.

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades under the stock symbol CLSD on NASDAQ.

What product does Clearside Biomedical currently have on the market?

Clearside Biomedical's product, XIPERE, is commercially available in the U.S.

What is the focus of Clearside Biomedical's technology?

Clearside Biomedical focuses on delivering therapies to the back of the eye using its SCS Microinjector.